Camatinib, an emerging therapeutic agent in the field of oncology, has attracted attention as a promising treatment for various cancers. It is a potent inhibitor of certain proteins involved in cancer cell growth and survival, specifically targeting the c-MET (mesenchymal-epithelial transition factor) pathway, which plays a crucial role in the progression of several types of malignancies. Camatinib’s targeted action and its ability to disrupt the c-MET signaling pathway make it a valuable candidate in the treatment of cancers where c-MET overexpression or mutation is implicated.